Evaluation of Diamine (1,1-Cyclobutane-Dicarboxylato-(2)-0,0')-CSP-4-2)Platinum (CBDCA-NSC-241240) and Cis-Dichloro-Trans-Dihydroxy-Bis-(Isoprpylamine)-Platinum IV (CHIP-NSC-256927) for Patients with Advanced (M1) and Recurrent Squamous Cell Cancer of the Head and Neck

Closed

Phase

Published

Abbreviated Title

Evaluation of Diamine (1,1-Cyclobutane-Dicarboxylato-(2)-0,0')-CSP-4-2)Platinum (CBDCA-NSC-241240) and Cis-Dichloro-Trans-Dihydroxy-Bis-(Isoprpylamine)-Platinum IV (CHIP-NSC-256927) for Patients with…

Activated

12/22/1983

Closed

09/27/1985

Publication Information Expand/Collapse

1987

Platinum analogs in recurrent and advanced head and neck cancer:A Southwest Oncology Group and Wayne State University Study.

M Al-Sarraf;B Metch;J Kish;J Ensley;JJ Rinehart;DE Schuller;C Coltman, Jr Cancer Treat Rep 71(7-8):723-726

Activity and toxicity of CBDCA and CHIP in patients with recurrentand advanced head and neck cancer.

M Al-Sarraf;J Kish;J Ensley;B Metch;J Rinehart;D Schuller;C Coltman, Jr ASCO :#C-485

1985

Activity of CHIP and CBDCA (platinum analogs) in recurrent epidermoid cancer of the head and neck(HNC) - randomized Phase II trial of WSU and the Southwest Oncology Group.

J Kish;J Ensley;M Al-Sarraf;D Von Hoff;D Schuller ASCO, #C-504